Active Biotech AB - Asset Resilience Ratio
Active Biotech AB (ACTI) has an Asset Resilience Ratio of 53.53% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Active Biotech AB for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2024)
This chart shows how Active Biotech AB's Asset Resilience Ratio has changed over time. See Active Biotech AB net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Active Biotech AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ACTI market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr9.10 Million | 53.53% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr9.10 Million | 53.53% |
Asset Resilience Insights
- Very High Liquidity: Active Biotech AB maintains exceptional liquid asset reserves at 53.53% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Active Biotech AB Industry Peers by Asset Resilience Ratio
Compare Active Biotech AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Active Biotech AB (2000–2024)
The table below shows the annual Asset Resilience Ratio data for Active Biotech AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 63.41% | Skr27.39 Million ≈ $2.95 Million |
Skr43.20 Million ≈ $4.65 Million |
-18.81pp |
| 2023-12-31 | 82.23% | Skr36.22 Million ≈ $3.90 Million |
Skr44.05 Million ≈ $4.74 Million |
+0.27pp |
| 2022-12-31 | 81.95% | Skr41.80 Million ≈ $4.50 Million |
Skr51.01 Million ≈ $5.49 Million |
-11.59pp |
| 2021-12-31 | 93.54% | Skr53.13 Million ≈ $5.72 Million |
Skr56.80 Million ≈ $6.11 Million |
+12.02pp |
| 2020-12-31 | 81.52% | Skr26.21 Million ≈ $2.82 Million |
Skr32.16 Million ≈ $3.46 Million |
-7.62pp |
| 2019-12-31 | 89.14% | Skr59.68 Million ≈ $6.42 Million |
Skr66.95 Million ≈ $7.21 Million |
+80.69pp |
| 2018-12-31 | 8.45% | Skr25.55 Million ≈ $2.75 Million |
Skr302.43 Million ≈ $32.55 Million |
+0.17pp |
| 2017-12-31 | 8.28% | Skr25.15 Million ≈ $2.71 Million |
Skr303.81 Million ≈ $32.70 Million |
-10.53pp |
| 2016-12-31 | 18.81% | Skr77.68 Million ≈ $8.36 Million |
Skr412.88 Million ≈ $44.43 Million |
+17.48pp |
| 2004-12-31 | 1.33% | Skr4.17 Million ≈ $449.19K |
Skr312.89 Million ≈ $33.67 Million |
-51.44pp |
| 2003-12-31 | 52.77% | Skr182.27 Million ≈ $19.62 Million |
Skr345.40 Million ≈ $37.17 Million |
+18.55pp |
| 2002-12-31 | 34.22% | Skr159.98 Million ≈ $17.22 Million |
Skr467.50 Million ≈ $50.31 Million |
-28.76pp |
| 2001-12-31 | 62.98% | Skr470.96 Million ≈ $50.68 Million |
Skr747.74 Million ≈ $80.47 Million |
+27.54pp |
| 2000-12-31 | 35.45% | Skr308.02 Million ≈ $33.15 Million |
Skr868.95 Million ≈ $93.51 Million |
-- |
About Active Biotech AB
Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat relapsed refractory multiple myeloma; Laquinimod, a mechanism which is in phase 1 for the treatment of severe inflammatory eye diseases, such as… Read more